PARK8 (LRRK2) Antibody (L893)

Synthetic Peptide

Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Polyclonal

120892

Purified Rabbit Polyclonal Antibody (Pab)

PARK8 (LRRK2) Antibody (L893) (Cat.#AP7099f) detects over-expressed human LRRK2 protein.

1:1000

WB

Formalin-fixed and paraffin-embedded human hepatocarcinoma reacted with PARK8 (LRRK2) Antibody (L893)(Cat.#AP7099f), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

1:10~50

Rabbit Ig

878-909

This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 878-909 amino acids from human PARK8(LRRK2).